Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1989 1
1990 1
1993 4
1994 3
1995 2
1998 1
1999 1
2000 3
2001 10
2002 15
2003 8
2004 13
2005 14
2006 18
2007 22
2008 25
2009 23
2010 29
2011 38
2012 44
2013 47
2014 66
2015 78
2016 67
2017 70
2018 70
2019 60
2020 67
2021 83
2022 80
2023 67
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

944 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Crondahl
Page 1
Epidemiology and Risk Factors for Dementia.
Dintica CS, Yaffe K. Dintica CS, et al. Psychiatr Clin North Am. 2022 Dec;45(4):677-689. doi: 10.1016/j.psc.2022.07.011. Epub 2022 Oct 14. Psychiatr Clin North Am. 2022. PMID: 36396272 Review.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. de Haas SL, et al. Breast Cancer Res. 2023 Jan 11;25(1):2. doi: 10.1186/s13058-022-01587-z. Breast Cancer Res. 2023. PMID: 36631725 Free PMC article. Clinical Trial.
BACKGROUND: KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II-III breast cancer. ...RESULTS: Biomarker analyses included …
BACKGROUND: KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplat …
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Hurvitz SA, et al. Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23. Lancet Oncol. 2018. PMID: 29175149 Clinical Trial.
We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. METHODS: We did a randomised, open-label phase 3 KRISTINE trial in 68 Translational Research In Oncology centres …
We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with …
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Hurvitz SA, et al. J Clin Oncol. 2019 Sep 1;37(25):2206-2216. doi: 10.1200/JCO.19.00882. Epub 2019 Jun 3. J Clin Oncol. 2019. PMID: 31157583 Free PMC article. Clinical Trial.
PURPOSE: The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2-positive stage II to III breast cancer. T-DM1+P led to a lowe …
PURPOSE: The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuz …
Urologic Oncology.
Burgess KE, DeRegis CJ. Burgess KE, et al. Vet Clin North Am Small Anim Pract. 2019 Mar;49(2):311-323. doi: 10.1016/j.cvsm.2018.11.006. Epub 2019 Jan 8. Vet Clin North Am Small Anim Pract. 2019. PMID: 30635132 Review.
Maintaining the Watch.
Morris K. Morris K. Am J Nurs. 2022 May 1;122(5):64. doi: 10.1097/01.NAJ.0000830776.31596.cd. Am J Nurs. 2022. PMID: 35447658
[Preimplantation genetic testing].
Løssl K, Bentzen JG, Petersen MR, Roos LS, Kjartansdóttir KR, Grøndahl ML, Troest B, Toft CLF, Pedersen IS, Diemer T, Ingerslev HJ. Løssl K, et al. Ugeskr Laeger. 2021 Nov 29;183(48):V04210378. Ugeskr Laeger. 2021. PMID: 34852911 Free article. Review. Danish.
944 results